[{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Not Applicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ 3E Bioventures"},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CG001419","moa":"TRK protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ Not Applicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"AZ-CICC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cullgen \/ AZ-CICC","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ AZ-CICC"},{"orgOrder":0,"company":"Cullgen","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Cullgen \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ Astellas Pharma"},{"orgOrder":0,"company":"Cullgen","sponsor":"Pulmatrix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"CG001419","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Cullgen","highestDevelopmentStatusID":"6","companyTruncated":"Cullgen \/ Cullgen"}]

Find Clinical Drug Pipeline Developments & Deals by Cullgen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The combined company will focus on targeted protein degradation technology with three programs, including CG001419, a potential first-in-class, highly active small molecule.

                          Brand Name : CG001419

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : CG001419

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Pulmatrix

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Under the terms of the agreement, Astellas and Cullgen aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ targeted protein degradation platform featuring novel E3 ligands with Astellas' drug discovery capabili...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $35.0 million

                          June 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Astellas Pharma

                          Deal Size : $120.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The financing will be used to accelerate development of Cullgen's promising pipeline of targeted protein degraders featuring novel E3 ligands to potentially introduce new treatment approaches for patients battling cancer using uSMITE, Cullgen’s Protein...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 08, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : AZ-CICC

                          Deal Size : $40.0 million

                          Deal Type : Financing

                          blank

                          04

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : CG001419 is a first-in-class, selective, potent oral targeted protein degrader for treatment of neurotrophic tyrosine receptor kinase fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast, and ...

                          Brand Name : CG001419

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 09, 2022

                          Lead Product(s) : CG001419

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases. Cullgen plan to file an IND later this year for our most advanced program, CG001419.

                          Brand Name : CG001419

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 25, 2021

                          Lead Product(s) : CG001419

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : 3E Bioventures

                          Deal Size : $50.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The first-in-class degraders developed by Cullgen efficiently degrade mutated, disease causing forms of the BRAF protein and subsequently inhibit cancer cell growth.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          April 07, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank